TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic ...

Delhi High Court bars Dr Reddy's and OneSource from selling semaglutide in India, supporting Novo Nordisk's patent rights as ...

The court’s intervention comes at a crucial time as Novo Nordisk gears up for the rollout of Wegovy, amid rising global ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

The research will focus on the use of GLP-1 receptor agonist medications and their possible cognitive benefits in aging ...

The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...

Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...

and dulaglutide (Trulicity). Semaglutide (Ozempic) and tirzepatide (Zepbound) were not included in the study. Obesity is associated with 13 cancers, and losing weight can slash that risk.

New Africa – stock.adobe.com In one of the two new studies, published in JAMA Neurology, researchers looked at how GLP-1 receptor agonists — drugs like semaglutide, dulaglutide and liraglutide ...